Dr JJP group is dedicated to exploring the quest behind prognosis and variable molecular targets responsible for aggravating neurodegeneration in the brain to develop various stimuli responsive- theranostic nanosystems. Using peptide-based skeleton, we try to develop a multimeric system for achieving targeted therapeutic outcomes. Harnessing the amino-acid transporters present in the brain, our peptide-based nanosystems could effectively be taken up across the blood-brain barrier, thereby breaking through the semi-permeable limiting membranes. Furthermore, tailoring the peptides in such a manner to induce self-fluorescence in the peptide nanostructures could enable diagnosis. We design the peptide nanocarriers loaded with desired therapeutic moieties and molecular drugs, including therapeutic protein/siRNA/aptamer for accomplishing desired therapeutic effect. We have successfully developed self-fluorescent tryptophan nanoparticles loaded with dopamine and several polyphenol drugs for their application as theranostics in Alzheimer’s  disease. Additionally, we also explored a modified dipeptide based nanoparticles arginine- dehydrophenylalanine nanoparticles conjugated with selenium for AD therapy. Furthermore, an acoustic stimuli-responsive nano system was developed in our lab for treating AD effectively. Our nano systems demonstrated superior efficacy in both cellular models as well as AD induced animal models. Thus, we aspire to further take these systems to clinical stages for healthcare advances. Currently, we are also exploring ultra-small DNA-peptide nano-assemblies for their applications in neurodegenerative disorders and stroke.